What is the recommended management for a patient with a positive high‑risk HPV test and a normal Pap smear?

Management of HPV-Positive with Normal Cytology

For a patient with positive high-risk HPV and normal Pap smear (NILM cytology), you have two evidence-based options: either repeat co-testing in 12 months, or perform immediate HPV genotyping for types 16 and 18 with reflex to colposcopy only if these high-risk genotypes are detected. 1

Primary Management Options

Option 1: Repeat Co-testing at 12 Months (Preferred by Most Guidelines)

• Return the patient for repeat HPV and cytology testing in 12 months. 1 This approach recognizes that the majority of HPV infections are transient and will clear spontaneously within this timeframe. 1

• At the 12-month follow-up visit:

  • If either test is positive (HPV positive OR cytology shows any abnormality), refer directly to colposcopy. 1
  • If both tests are negative, return to routine screening intervals (every 3 years for cytology alone or every 5 years for co-testing in women 30-65 years). 1, 2

• This strategy is supported by large cohort studies demonstrating that the short-term risk of CIN3+ in HPV-positive, cytology-negative women is far below the 8-10% threshold used for immediate colposcopy referral. 1

Option 2: Immediate HPV Genotyping for Types 16 and 18

• Perform reflex genotyping specifically for HPV 16 and/or HPV 18 immediately. 1 This option is appropriate when genotyping is readily available and allows for more immediate risk stratification.

• If HPV 16 positive:

  • Refer directly to colposcopy without delay. 1, 3 HPV 16 confers the highest absolute risk of CIN3+ among all carcinogenic types and mandates immediate evaluation. 1, 3

• If HPV 18 positive (but HPV 16 negative):

  • Refer directly to colposcopy. 1 While HPV 18 carries lower immediate CIN3+ risk than HPV 16, it has a disproportionately high etiologic fraction for adenocarcinoma, particularly invasive adenocarcinoma. 1, 3

• If both HPV 16 and 18 are negative (other high-risk types present):

  • Proceed with repeat co-testing at 12 months and manage as described in Option 1. 1

Critical Evidence Supporting These Recommendations

• The 2-year risk of CIN3+ in HPV-positive, cytology-negative women is substantially lower than the clinical action threshold. Large prospective cohort studies consistently show this population has insufficient short-term risk to justify immediate colposcopy for all patients. 1

• HPV 16 is uniquely high-risk. In the Kaiser Permanente Northern California cohort, HPV 16 positivity elevated immediate CIN3+ risk sufficiently to mandate colposcopic referral even with negative cytology. 3 HPV 16 accounts for the majority of cervical cancers and confers much higher absolute risk than any other carcinogenic type. 1

• Adenocarcinoma risk with HPV 18. From the Katki analysis, 63% of adenocarcinomas diagnosed over 5 years followed an HPV-positive, cytology-negative co-test result. 1 HPV 18 has a disproportionately high etiologic fraction for adenocarcinoma compared to squamous cell carcinoma. 1

What NOT to Do: Common Pitfalls

• Do NOT refer all HPV-positive, cytology-negative women directly to colposcopy. 1 This was explicitly dismissed by consensus guidelines as it would result in massive over-referral given the low short-term CIN3+ risk in this population. 1

• Do NOT perform genotyping for individual HPV types other than 16 and 18. 1 While types like HPV 31,33,52, and 58 carry intermediate risk, there is insufficient evidence to support their use in clinical decision-making for this specific scenario. 1

• Do NOT use non-HPV biomarkers. 1 As of the most recent guidelines, there is insufficient evidence to support the use of alternative molecular markers in HPV-positive, cytology-negative women. 1

• Do NOT delay the 12-month follow-up. Recent cohort data from the PROSPR II study showed that less than half of patients with HPV-positive/NILM results received guideline-concordant surveillance testing within the recommended timeframe, and 10 cancers were diagnosed among those who remained untested. 4 This represents a critical care gap.

Age and Risk Considerations

• For women ≥30 years (the typical co-testing population): The bimodal age distribution of HR-HPV shows peaks in very young women (≤20 years) and older women (≥61 years). 5 However, in the 30-65 age range where co-testing is standard, HPV positivity with normal cytology still warrants the conservative 12-month surveillance approach unless HPV 16/18 is detected. 1

• The negative predictive value of a negative HPV test approaches 99.7-100% for CIN3+ over 2 years. 6 This underscores why repeat testing at 12 months is safe and effective—most transient infections will have cleared, and those with persistent infection can then be appropriately triaged.

Extended Genotyping Considerations (Newer Evidence)

• If extended genotyping beyond HPV 16/18 is available (e.g., Onclarity assay): Recent 2025 consensus guidelines suggest that for certain intermediate-risk genotypes (HPV 31,33/58,35/39/68,45,51,52), cytology or dual-stain triage may be used rather than immediate colposcopy. 7 However, for the lowest-risk genotypes (HPV 56/59/66), repeat HPV testing in 1 year is recommended. 7

• This extended genotyping approach is acceptable but not required. 7 The traditional two-option algorithm (12-month repeat co-testing vs. HPV 16/18 genotyping) remains the standard of care. 1

Documentation and Patient Counseling

• Counsel patients that their short-term cancer risk is very low but not zero. 1 Emphasize the importance of returning for the 12-month follow-up, as adherence to surveillance is a documented problem. 4

• Explain that most HPV infections clear spontaneously within 12 months. 1 This helps reduce anxiety while reinforcing the need for follow-up.

• If HPV 16 or 18 is detected, explain the higher risk profile. 1, 3 These genotypes require immediate colposcopy because they carry significantly elevated risk of high-grade disease and cancer.